Renovaro Management
Management criteria checks 2/4
Renovaro's CEO is Mark Dybul, appointed in Jul 2021, has a tenure of 2.83 years. total yearly compensation is $1.41M, comprised of 47.3% salary and 52.7% bonuses, including company stock and options. directly owns 0.046% of the company’s shares, worth €92.28K. The average tenure of the management team and the board of directors is 1.8 years and 4.4 years respectively.
Key information
Mark Dybul
Chief executive officer
US$1.4m
Total compensation
CEO salary percentage | 47.3% |
CEO tenure | 2.8yrs |
CEO ownership | 0.05% |
Management average tenure | 1.8yrs |
Board average tenure | 4.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | -US$41m |
Sep 30 2023 | n/a | n/a | -US$41m |
Jun 30 2023 | US$1m | US$665k | -US$40m |
Mar 31 2023 | n/a | n/a | -US$107m |
Dec 31 2022 | n/a | n/a | -US$109m |
Sep 30 2022 | n/a | n/a | -US$111m |
Jun 30 2022 | US$11m | US$850k | -US$113m |
Mar 31 2022 | n/a | n/a | -US$41m |
Dec 31 2021 | n/a | n/a | -US$38m |
Sep 30 2021 | n/a | n/a | -US$35m |
Jun 30 2021 | US$430k | US$430k | -US$27m |
Mar 31 2021 | n/a | n/a | -US$13m |
Dec 31 2020 | n/a | n/a | -US$11m |
Sep 30 2020 | n/a | n/a | -US$10m |
Jun 30 2020 | US$1m | US$430k | -US$11m |
Mar 31 2020 | n/a | n/a | -US$6m |
Dec 31 2019 | n/a | n/a | -US$7m |
Sep 30 2019 | n/a | n/a | -US$22m |
Jun 30 2019 | US$2m | US$210k | -US$18m |
Mar 31 2019 | n/a | n/a | -US$21m |
Dec 31 2018 | n/a | n/a | -US$21m |
Sep 30 2018 | n/a | n/a | -US$6m |
Jun 30 2018 | US$76k | n/a | -US$6m |
Compensation vs Market: Mark's total compensation ($USD1.41M) is above average for companies of similar size in the German market ($USD706.93K).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
CEO
Mark Dybul (59 yo)
2.8yrs
Tenure
US$1,405,433
Compensation
Honorable Dr. Mark R. Dybul, M.D., serves as Chief Executive Officer at Enochian Biosciences, Inc. since July 1, 2021. He served as Executive Vice-Chair of Renovaro Biosciences Inc. (formerly known as Enoc...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, Director & Member of HBV Scientific Advisory Board | 2.8yrs | US$1.41m | 0.046% $ 92.3k | |
COO and Executive VP for Research & Development | 1.5yrs | US$881.57k | 0% $ 0 | |
Co-Founder & Inventor | no data | no data | 8.66% $ 17.3m | |
Interim Chief Financial Officer | less than a year | no data | no data | |
Senior Vice President for Clinical Operations | 2.1yrs | no data | no data |
1.8yrs
Average Tenure
59yo
Average Age
Experienced Management: 2Q5's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, Director & Member of HBV Scientific Advisory Board | 6.3yrs | US$1.41m | 0.046% $ 92.3k | |
Member of HBV Scientific Advisory Board | 2.8yrs | no data | no data | |
Lead Independent Board Member | 4.4yrs | US$133.21k | 0% $ 0 | |
Independent Director | 6.2yrs | US$133.62k | 0% $ 0 | |
Chairperson of HBV Cure Scientific Advisory Board & Independent Director | 4.4yrs | US$124.71k | 0% $ 0 | |
Member of HBV Scientific Advisory Board | 3.8yrs | no data | no data | |
Independent Director | 3yrs | US$131.25k | 0% $ 0 | |
Chairman of the Board | 6.9yrs | US$153.71k | 0% $ 0 | |
Chairman of HIV Scientific Advisory Board | 5.8yrs | no data | no data | |
Member of HIV Scientific Advisory Board | 6.3yrs | no data | no data | |
Member of HBV Scientific Advisory Board | 3.8yrs | no data | no data | |
Chairman of Scientific Advisory Board | less than a year | no data | no data |
4.4yrs
Average Tenure
60yo
Average Age
Experienced Board: 2Q5's board of directors are considered experienced (4.4 years average tenure).